Glioblastoma treatment hopes turn to combining peptide vaccines with Immuno-Oncology products

Rintega has performed consistently with prior Phase II studies but the control arm has significantly outperformed expectations

glioblastoma-multiforme

(Photo Courtesy: www.brain-surgery.com)

The termination of Celldex's Phase III trial assessing its peptide-based vaccine therapy, Rintega, in newly-diagnosed glioblastoma patients, represents a blow to the treatment space as hopes for improved therapies turn instead to Opdivo and drugs combining peptide vaccines with immuno-oncology products, according to analysts with research and consulting firm GlobalData.

In a press release on March 7, 2016, Celldex stated that the trial was terminated because "Rintega has performed consistently with prior Phase II studies but the control arm has significantly outperformed expectations."

Dr Dan Roberts, GlobalData's Senior Analyst covering Oncology and Hematology, explains: "The fact that this study involved a control arm which outperformed historical controls was not unexpected, as patients who were enrolled in this trial underwent total resection and had no evidence of a progressive disease."

Indeed, as stated in GlobalData's glioblastoma report from December 2015, "comparison to historical values must be interpreted with caution, as these patients typically have higher survival than the general glioblastoma population."

Dr Maxime Bourgognon, GlobalData's Analyst covering Oncology and Hematology, says that despite Rintega's disappointments, there are reasons for glioblastoma patients to be optimistic, as immunotherapy agents hold great promise for those faced with high unmet needs and extremely poor survival.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X